Avalo’s abdakibart showed strong results in reducing HS symptoms in a Phase 2 trial, with a favorable safety profile and better outcomes than placebo.
Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.
Viridian's drug for thyroid eye disease showed strong Phase 3 results, improving eye symptoms with simple injections and possible home use.
UCB buys Candid Therapeutics for $2B+ to develop immune disease drug that may reset immune system; rivals’ stocks rise.
Mirum’s drug volixibat reduced severe itching in PSC patients in a Phase 2 trial; next step is FDA filing in 2026.
Garda raised bid to $21.80/share cash to buy Assertio, boosting stock ~17%. Deal gives shareholders higher, certain payout.
